3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
350
Polycystic Ovary Syndrome
39
Endometrial Neoplasms
22
Neoplasm Metastasis
21
Ovarian Neoplasms
16
Infertility
12
Neoplasms
11
Fallopian Tube Neoplasms
8
Advanced Breast Cancer
8
Triple Negative Breast Neoplasms
7
Carcinoma, Intraductal, Noninfiltrating
7
Carcinoma, Ductal, Breast
7
Breast Neoplasms, Male
7
Recurrence
6
Osteoporosis
6
Carcinoma, Lobular
6
Breast Diseases
6
Breast Carcinoma In Situ
6
Prostatic Neoplasms
5
Leiomyoma
4
Infertility, Female
4
Hereditary Sensory and Autonomic Neuropathies
4
Breast Cancer Metastatic
4
Neoplasms, Hormone-Dependent
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Non-Small-Cell Lung
3
Anovulation
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Interventions
Cyclophosphamide
38
Paclitaxel
22
Epirubicin
21
Trastuzumab
20
Docetaxel
20
Doxorubicin
19
Carboplatin
15
Radiotherapy
13
Taxes
11
Filgrastim
11
Neoadjuvant Therapy
9
Bevacizumab
9
Fluorouracil
8
pembrolizumab
7
Tamoxifen
7
Albumin-Bound Paclitaxel
7
Capecitabine
6
pertuzumab
5
Thiotepa
5
Peripheral Blood Stem Cell Transplantation
5
Lapatinib
5
130-nm albumin-bound paclitaxel
5
pegfilgrastim
4
Granulocyte Colony-Stimulating Factor
4
Cisplatin
4
Chemotherapy, Adjuvant
4
tipifarnib
3
eribulin
3
Surgical Procedures, Operative
3
Specimen Handling
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Inflammatory Breast Neoplasms
×
Letrozole
×
Clear all
NCT02221999
2023-08-29
SHPD002
RenJi Hospital
Phase 2/3
Active not recruiting
250 enrolled